Ligand id: 5585

Name: degarelix

Structure and Physico-chemical Properties

2D Structure
No information available.
Summary of Clinical Use
Approved to treat patients with advanced prostate cancer.
Mechanism Of Action and Pharmacodynamic Effects
Degarelix is a pituitary gonadotropin-releasing hormone (GnRH) receptor anatgonist. GnRH receptor antagonism reduces the release of the gonadotropins LH and FSH which consequently reduces testosterone levels. Reducing testosterone levels is important for patients with testosterone-sensitive prostate cancer.
External links